In this issue:
Validation of the O-RADS lexicon and OITA-2 for risk stratification
Progress in individualised therapy for ovarian cancer
Olaparib combo maintenance prolongs PFS regardless of age
CHIVA: nintedanib not suitable in neoadjuvant setting
Mirvetuximab combo promising for FRα-expressing tumours
NAMPT inhibitors may counter PARP inhibitor resistance
Financial toxicity in BRCA1 and BRCA2 carriers
Intrathoracic surgery feasible as part of primary cytoreduction
Minimally invasive vs open pelvic exenteration
Maintenance niraparib effective for recurrent platinum-sensitive disease
Please login below to download this issue (PDF)